UK Study Finds Pfizer/Bristol Myers Clotting Drug Does Not Help in COVID

 

• According to a U.K. trial, Eliquis (apixaban), widely prescribed for COVID-19, did not help patients recovering from moderate and severe COVID.
• The drug used after discharge from the hospital does not lessen the chances for COVID-19 patients of readmission or improve survival.
• The results were shared with the Financial Times.
• Eliquis is indicated to reduce the risk of stroke and blood clots in people with nonvalvular atrial fibrillation, a type of irregular heartbeat.
• Apixaban is jointly commercialized by Pfizer Inc 
  PFE-0.17%+ Free Alerts
   and Bristol Myers Squibb Co 
  BMY-0.03%+ Free Alerts
  .
• Researchers also found that a small number of cases caused serious harm. 
• Around 29.1% of people given the drug ended up back in the hospital or died, compared with 30.8% receiving standard care. 
• The 402-subject study showed no benefit from Apixaban regarding the number of days patients remained alive and out of the hospital 60 days after their initial discharge. 
• The study will continue to test another drug called Atorvastatin, a widely used lipid-lowering drug, or "statin," that acts on other mechanisms of disease that are thought to be important in COVID.

https://www.benzinga.com/general/biotech/22/11/29866620/uk-study-finds-pfizerbristol-myers-clotting-drug-does-not-help-covid-19-patients